Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 10, 2008, Pages 1119-1126

  Chakra, Mohammad ^a   Pujol, Jean Louis ^a,d   Lamy, Pierre Jean ^b   Bozonnat, Marie Cecile ^c   Quantin, Xavier ^a   Jacot, William ^a   Daurès, Jean Pierre ^c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b CENTRE VAL D AURELLE   (France)

^c UNIV MONTPELLIER   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Angiogenesis; Circulating vascular endothelial growth factor; Non small cell lung cancer; Prognosis

Indexed keywords

CISPLATIN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; VASCULOTROPIN; ANTIGEN CYFRA21.1; ENOLASE; KERATIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; BLOOD; LARGE CELL CARCINOMA; LUNG TUMOR; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; ROC CURVE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58949087472     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318187464e     Document Type: Article

References (44)

1. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995;13:1221-1230.
2. Charloux A, Hedelin G, Dietemann A, et al. Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer 1997;17:123-134.
3. Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004;90:1905-1911.
4. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004;90:2097-2105.
5. Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 2006;1:441-446.
6. Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer 2001;92:2639-2647.
7. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CW Jr. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997;89:1580-1586.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2007;356: 1373-1374.
9. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S:LA7514.
10. Laack E, Scheffler A, Burkholder I, et al. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 2005;50:51-58.
11. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, in collaboration with L. H. Sobin and pathologists from 14 countries. Histological Typing of Lung and Pleural Tumors, 3rd ed. Berlin: Springer, 1999.
12. Zubrod C, Schneiderman M, Frei EJ. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960; 11:7-33.
13. Sobin LH, Wittekind C. Lung and pleural tumours. In Cancer IUA (Ed.), TNM Classification of Malignant Tumours, 6th Ed. New York: Wiley & Sons, 2002. Pp. 99-103.
14. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004:CD002140.
15. Hanley JA, McNeil BJ. The meaning and use of area below the receiver operating characteristic curves. Radiology 1982;143:29-36.
16. Vida S. A computer program for non-parametric receiver operating characteristic analysis. Comput Methods Programs Biomed 1993;40:95-101.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
18. Cox JD, Yesner RA. Causes of treatment failure and death in carcinoma of the lung. Yale J Biol Med 1981;54:201-207.
19. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20:3906-3927.
20. Kadota K, Huang CL, Liu D, et al. The clinical significance of lym-phangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer 2008;44:1057-1067.
21. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endo- thelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000;82:1427-1432.
22. Mino N, Takenaka K, Sonobe M, et al. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol 2007;95:250-257.
23. Leinonen T, Pirinen R, Böhm J, Johansson R, Kosma VM. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol 2008;23:693-700.
24. Yamamura T, Nakanishi K, Hiroi S. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in non-small cell lung carcinomas. Lung Cancer 2002;35:249-255.
25. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 2006;65:1536-1543.
26. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-1225.
27. Hyodo I, Doi T, Endo H, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998;34:2041-2045.
28. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001;19:577-583.
29. Ustuner Z, Saip P, Yasasever V, et al. Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Med Oncol 2008; (Epub ahead of print).
30. Choi JH, Kim HC, Lim HY, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer 2001;33:171-179.
31. Laack E, Köhler A, Kugler C, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13:1550-1557.
32. Katsabeki-Katsafli A, Kerenidi T, Kostikas K, et al. Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer. Lung Cancer 2008;60:271-276.
33. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005;23:193-200.
34. Bodenmüller H, Ofenloch-Haühnle B, Lane EB, Dessauer A, Böttger V, Donié F. Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1. Int J Biol Markers 1994;9:75-81.
35. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immu-noradiometric assay as a marker of lung cancer. Cancer Res 1993;53: 61-66.
36. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001;33:89-94.
37. Le Chevalier T, Pujol JL, Douillard Y, et al. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin Oncol 1994;21:28-34.
38. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-1412.
39. Jacot W, Pujol JL, Boher JM, Lamy JM. Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. Br J Cancer 2004;91:430-433.
40. Niklińska W, Burzykowski T, Chyczewski L, Nikliński J. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung Cancer 2001;34(Suppl 2):S59-S64.
41. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer 2001;33:125-132.
42. Baillie R, Carlile J, Pendleton N, Schor AM. Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol 2001;54:116-120.
43. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with non-small cell lung carcinoma. Cancer 2003;97:457-464.
44. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23:3243-3256.